{"id":746,"date":"2020-06-15T15:16:34","date_gmt":"2020-06-15T14:16:34","guid":{"rendered":"https:\/\/blog.iese.edu\/entrepreneurship\/?p=746"},"modified":"2021-07-27T12:31:08","modified_gmt":"2021-07-27T11:31:08","slug":"iese-finaves-invests-neurotech-inbrain","status":"publish","type":"post","link":"https:\/\/blog.iese.edu\/entrepreneurship\/2020\/06\/15\/iese-finaves-invests-neurotech-inbrain\/","title":{"rendered":"IESE\u2019s Finaves Invests in Neurotech Startup InBrain"},"content":{"rendered":"<p><a href=\"https:\/\/blog.iese.edu\/entrepreneurship\/files\/2020\/06\/InBrain_blog.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-748 aligncenter\" src=\"https:\/\/blog.iese.edu\/entrepreneurship\/files\/2020\/06\/InBrain_blog.jpg\" alt=\"\" width=\"600\" height=\"450\" srcset=\"https:\/\/blog.iese.edu\/entrepreneurship\/files\/2020\/06\/InBrain_blog.jpg 600w, https:\/\/blog.iese.edu\/entrepreneurship\/files\/2020\/06\/InBrain_blog-300x225.jpg 300w, https:\/\/blog.iese.edu\/entrepreneurship\/files\/2020\/06\/InBrain_blog-500x375.jpg 500w\" sizes=\"auto, (max-width: 600px) 100vw, 600px\" \/><\/a><\/p>\n<p><a href=\"https:\/\/www.iese.edu\/entrepreneurship\/finaves\/\"><strong>Finaves<\/strong> V<\/a>, IESE\u2019s venture capital fund, is part of a group of investors providing \u20ac900,000 in financing for <strong><a href=\"http:\/\/www.inbrain-neuroelectronics.com\/\">InBrain Neuroelectronics<\/a><\/strong>, a startup that is developing graphene-based technologies to treat neurological disorders such as epilepsy and Parkinson\u2019s with unprecedented precision.<\/p>\n<p>Finaves contributed \u20ac150,000 to the round, which was led by <strong>Sabadell-Asabys<\/strong> and <strong>Alta Life Sciences<\/strong>, two Barcelona-based funds that specialize in healthcare. Other partners in the round were the <strong>Institut Catal\u00e1 de Finances (ICF)<\/strong>, the research center <strong>Institut Catal\u00e1 de Nanoci\u00e9ncia i Nanotecnologia (ICN2)<\/strong> and venture capital firm <strong>Ysios Capital<\/strong>.<\/p>\n<p>InBrain is founded and managed by a team of leading experts in the fields of neuroelectronics and business management. <strong>CEO and co-founder Carolina Aguilar<\/strong> worked for more than a decade as business director of medical technology and services company Medtronic, responsible for the global commercialization of the company\u2019s neurological business, with a particular focus on deep brain stimulation (DBS).<\/p>\n<p><strong>Jose Garrido, founder and chief scientific officer<\/strong>, is a renowned expert in the field of graphene technology, and <strong><a href=\"https:\/\/www.iese.edu\/faculty-research\/faculty\/mario-capizzani\/\">Mario Capizzani<\/a>, co-founder and chief commercial officer, is a marketing professor at IESE<\/strong>.<\/p>\n<p>InBrain, a spin-off of ICN2, is <strong>developing neuroelectronic therapies that use graphene interfaces to stimulate areas of the brain in better and more targeted ways<\/strong>. The \u200b\u200bthinnest known material, graphene is also incredibly strong, is an excellent conductor and has interesting light absorption abilities. Due to its superior material characteristics, graphene-based implants can be designed smaller than traditional metal-based implants, which allows for a more precise stimulation of diseased brain areas and fewer side effects.<\/p>\n<p>Today up to 50% of DBS candidates refuse therapy do to its invasiveness and more than 35% drug resistant brain disorder patients remain without treatment. InBrain\u2019s technology will help these patients by offering a less invasive more efficient treatment of their disease.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Finaves V, IESE\u2019s venture capital fund, is part of a group of investors providing \u20ac900,000 in financing for InBrain Neuroelectronics, a startup that is developing graphene-based technologies to treat neurological disorders such as epilepsy and Parkinson\u2019s with unprecedented precision. Finaves contributed \u20ac150,000 to the round, which was led by Sabadell-Asabys and Alta Life Sciences, two [&hellip;]<\/p>\n","protected":false},"author":2207,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[157,159,64812],"tags":[110910,918,80159],"coauthors":[111818],"class_list":["post-746","post","type-post","status-publish","format-standard","hentry","category-entrepreneurship","category-investors","category-startups","tag-finaves","tag-investment","tag-startup"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/blog.iese.edu\/entrepreneurship\/wp-json\/wp\/v2\/posts\/746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.iese.edu\/entrepreneurship\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.iese.edu\/entrepreneurship\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.iese.edu\/entrepreneurship\/wp-json\/wp\/v2\/users\/2207"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.iese.edu\/entrepreneurship\/wp-json\/wp\/v2\/comments?post=746"}],"version-history":[{"count":5,"href":"https:\/\/blog.iese.edu\/entrepreneurship\/wp-json\/wp\/v2\/posts\/746\/revisions"}],"predecessor-version":[{"id":752,"href":"https:\/\/blog.iese.edu\/entrepreneurship\/wp-json\/wp\/v2\/posts\/746\/revisions\/752"}],"wp:attachment":[{"href":"https:\/\/blog.iese.edu\/entrepreneurship\/wp-json\/wp\/v2\/media?parent=746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.iese.edu\/entrepreneurship\/wp-json\/wp\/v2\/categories?post=746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.iese.edu\/entrepreneurship\/wp-json\/wp\/v2\/tags?post=746"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blog.iese.edu\/entrepreneurship\/wp-json\/wp\/v2\/coauthors?post=746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}